News | Pacemakers | December 12, 2022

Global Pacemakers Market Set to Grow at 5.4% CAGR Over Next 3 Years

The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases.

Getty Images


December 12, 2022 —  The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases. Among pacemakers, dual chamber pacemakers are the fastest growing subsegment, growing at a rate of 5.6%, reveals GlobalData, a leading data and analytics company.

GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025. That brings the price of one pacemaker from $4730 to $4260, a reduction of almost $500 in just three years.

Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, comments: “The continuing demand for pacemakers in emerging countries can be attributed to affordable prices, easy availability in healthcare centers and favorable physician perception. The need for a large number of devices to cater for the substantial patient population in countries such as India and China will neutralize the loss due to reduced average prices and help to sustain the growth of revenues from this market.”

Advancing technology will propel the use of pacemakers with future improvements addressing the current limitations of the system: invasiveness. Aadvanced technology will make the pacemakers smaller in size and easier to implant.

Leadless pacemaker implantations have been found to be less invasive, improved quality of life, and reduced post-operative complications compared to traditional pacemakers.

Stinchcombe concludes: “In 2021, Medtronic was the only manufacturer to manufacture leadless pacemakers in this market and continues to be remain the sole manufacturer into 2022. However, competitors such as Abbott Medical currently have leadless pacemakers undergoing clinical trial and are set to give tough competition to Medtronic.”

For more information: www.globaldata.com


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now